Introduction: Severe asthma occurs in 5–10% of asthmatic patients, with nasal polyposis as one of the most frequent comorbidity. Benralizumab was recently marketed, thus we could analyse its effects in real-life in severe asthma, and compare the effects of the drug in patients with and without polyposis. Methods: Patients with severe asthma, receiving Benralizumab were enrolled in Italian asthma centres. The efficacy criteria for asthma (exacerbation rate, oral corticosteroid intake, hospitalizations, pulmonary function, exhaled nitric oxide) were evaluated at baseline and after 24 weeks of treatment. Patients were then sub-analysed according to the presence/absence of nasal polyposis. Results: Fifty-nine patients with severe uncontrolled asthma (21 males, age range 32–78) and treated with benralizumab for at least 24 weeks has been evaluated, showing significant improvements in asthma-related outcomes, except for pulmonary function and exhaled nitric oxide. This included a reduction in the sino-nasal outcome-22 score versus baseline of 13.7 points (p = .0037) in the 34 patients with nasal polyposis. Anosmia disappeared in 31% patients (p = .0034). When comparing the groups with and without nasal polyposis, a similar reduction of exacerbations was seen, with a greater reduction of the steroid dependence in patients with polyposis (−72% vs −53%; p < .0001), whereas lung function was significantly more improved (12% vs 34%, p = .0064) without polyposis patients. Conclusions: Benralizumab, after 6 months of treatment, confirmed its efficacy in severe asthma, and also in nasal polyposis, which is the most frequent comorbidity. The efficacy of Benralizumab in reducing steroid dependence was even higher in patients with polyposis.
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis / D. Bagnasco, L. Brussino, M. Bonavia, E. Calzolari, M. Caminati, C. Caruso, M. D'Amato, L. De Ferrari, F. Di Marco, G. Imeri, D. Di Bona, A. Gilardenghi, G. Guida, C. Lombardi, M. Milanese, A. Nicolini, A.M. Riccio, G. Rolla, P. Santus, G. Senna, G. Passalacqua. - In: RESPIRATORY MEDICINE. - ISSN 0954-6111. - 171(2020 Sep).
|Titolo:||Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis|
|Parole Chiave:||Anti IL-5r; Benralizumab; Nasal polyposis; Real life; Severe asthma|
|Settore Scientifico Disciplinare:||Settore MED/10 - Malattie dell'Apparato Respiratorio|
Settore MED/09 - Medicina Interna
Settore MED/31 - Otorinolaringoiatria
|Data di pubblicazione:||set-2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.rmed.2020.106080|
|Appare nelle tipologie:||01 - Articolo su periodico|